Skip to content

Study · Observational study · n = 13 · 2026

10 results

Effects of semaglutide, a GLP-1 receptor agonist, on food preferences in Japanese subjects with type 2 diabetes and visceral fat accumulation.

Hara T, Fujishima Y, Kimura Y, Fujii K, Kawachi Y, Nagao H, Obata Y, Fukuda S, Nagai N, Nishizawa H, Shimomura I

Endocrine journal29 Jan 2026Cited by 2 (Europe PMC)

PMID41605684 (opens in a new tab)PMCIDPMC13195457 (opens in a new tab)DOI10.1507/endocrj.ej25-0402 (opens in a new tab)PepBankPUB-41605684
Read at sourcePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In Japanese adults with obese type 2 diabetes, HbA1c fell by 1.1% in the semaglutide group.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, HbA1c fell during semaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 13

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −1.1%
    Sema group

    Source sentences

    Summary
    The Sema group showed significant decreases in HbA1c levels (-1.1%)
    1 context sentence
    Summary · context
    In this retrospective observational study, we enrolled 32 obese subjects with T2DM who were hospitalized for glycemic control, including 20 who started semaglutide treatment (the Sema group) and 12 who did not receive GLP-1RA therapy.
  2. 02HumanObservational studyEfficacy outcome

    In Japanese adults with obese type 2 diabetes, body weight fell by 5.7 kg in the semaglutide group.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, body weight fell during semaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 13

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Body weight change
    −5.7 kg
    Sema group

    Source sentences

    Summary
    body weight (-5.7 kg)
    1 context sentence
    Summary · context
    In this retrospective observational study, we enrolled 32 obese subjects with T2DM who were hospitalized for glycemic control, including 20 who started semaglutide treatment (the Sema group) and 12 who did not receive GLP-1RA therapy.
  3. 03HumanObservational studyEfficacy outcome

    In Japanese adults with obese type 2 diabetes on semaglutide, fat loss exceeded skeletal muscle loss.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes on semaglutide, the body lost more fat than muscle.

    Peptide
    Semaglutide
    Outcome
    DecreaseFat loss versus skeletal muscle loss
    Study

    n = 13

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    with fat loss exceeding skeletal muscle loss.
    1 context sentence
    Summary · context
    In this retrospective observational study, we enrolled 32 obese subjects with T2DM who were hospitalized for glycemic control, including 20 who started semaglutide treatment (the Sema group) and 12 who did not receive GLP-1RA therapy.
  4. 04HumanObservational studyEfficacy outcome

    In Japanese adults with obese type 2 diabetes on semaglutide, eating behavior scores for Eating Motives, Way of Eating and Dietary Content decreased significantly.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes on semaglutide, scores for eating motives, way of eating and diet content went down.

    Peptide
    Semaglutide
    Outcome
    DecreaseEating behavior scores
    Study

    n = 13

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Significant decreases were observed in eating behavior scores for "Eating Motives," "Way of Eating," and "Dietary Content."
    1 context sentence
    Summary · context
    In this retrospective observational study, we enrolled 32 obese subjects with T2DM who were hospitalized for glycemic control, including 20 who started semaglutide treatment (the Sema group) and 12 who did not receive GLP-1RA therapy.
  5. 05HumanObservational studyEfficacy outcome

    In Japanese adults with obese type 2 diabetes, semaglutide reduced preferences for sweet and non-sweet carbohydrates.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, semaglutide lowered the liking for sweet and non-sweet carbohydrate foods.

    Peptide
    Semaglutide
    Outcome
    DecreasePreference for carbohydrates
    Study

    n = 13

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    semaglutide significantly reduced preferences for sweet and non-sweet carbohydrates and non-sweet fats, without changing protein or dietary fiber preferences.
    1 context sentence
    Summary · context
    In this retrospective observational study, we enrolled 32 obese subjects with T2DM who were hospitalized for glycemic control, including 20 who started semaglutide treatment (the Sema group) and 12 who did not receive GLP-1RA therapy.
  6. 06HumanObservational studyEfficacy outcome

    In Japanese adults with obese type 2 diabetes, semaglutide reduced preferences for non-sweet fats.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, semaglutide lowered the liking for non-sweet fatty foods.

    Peptide
    Semaglutide
    Outcome
    DecreasePreference for non-sweet fats
    Study

    n = 13

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    semaglutide significantly reduced preferences for sweet and non-sweet carbohydrates and non-sweet fats
    1 context sentence
    Summary · context
    In this retrospective observational study, we enrolled 32 obese subjects with T2DM who were hospitalized for glycemic control, including 20 who started semaglutide treatment (the Sema group) and 12 who did not receive GLP-1RA therapy.
  7. 07HumanObservational studyEfficacy outcome

    In Japanese adults with obese type 2 diabetes, semaglutide did not change preferences for protein.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, semaglutide did not change the liking for protein foods.

    Peptide
    Semaglutide
    Outcome
    No significant changePreference for protein
    Study

    n = 13

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    without changing protein or dietary fiber preferences.
    1 context sentence
    Summary · context
    In this retrospective observational study, we enrolled 32 obese subjects with T2DM who were hospitalized for glycemic control, including 20 who started semaglutide treatment (the Sema group) and 12 who did not receive GLP-1RA therapy.
  8. 08HumanObservational studyEfficacy outcome

    In Japanese adults with obese type 2 diabetes, semaglutide did not change preferences for dietary fiber.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, semaglutide did not change the liking for high-fiber foods.

    Peptide
    Semaglutide
    Outcome
    No significant changePreference for dietary fiber
    Study

    n = 13

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    without changing protein or dietary fiber preferences.
    1 context sentence
    Summary · context
    In this retrospective observational study, we enrolled 32 obese subjects with T2DM who were hospitalized for glycemic control, including 20 who started semaglutide treatment (the Sema group) and 12 who did not receive GLP-1RA therapy.
  9. 09HumanObservational studyEfficacy outcome

    In Japanese adults with obese type 2 diabetes on semaglutide, preferences for Japanese staple foods such as white rice and udon/soba fell significantly.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes on semaglutide, the liking for staple foods such as white rice and noodles went down.

    Peptide
    Semaglutide
    Outcome
    DecreasePreference for Japanese staple foods
    Study

    n = 13

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    significant reductions were observed in preferences for Japanese staple foods (e.g., white rice and udon/soba)
    1 context sentence
    Summary · context
    In this retrospective observational study, we enrolled 32 obese subjects with T2DM who were hospitalized for glycemic control, including 20 who started semaglutide treatment (the Sema group) and 12 who did not receive GLP-1RA therapy.
  10. 10HumanObservational studyEfficacy outcome

    In Japanese adults with obese type 2 diabetes on semaglutide, preferences for high-fat snacks fell significantly.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes on semaglutide, the liking for high-fat snacks went down.

    Peptide
    Semaglutide
    Outcome
    DecreasePreference for high-fat snacks
    Study

    n = 13

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    and high-fat snacks.
    1 context sentence
    Summary · context
    In this retrospective observational study, we enrolled 32 obese subjects with T2DM who were hospitalized for glycemic control, including 20 who started semaglutide treatment (the Sema group) and 12 who did not receive GLP-1RA therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.